Interpretation of The "14th Five-Year Plan" For the Development of China Pharmaceutical Industry
For the newly released "14th Five-year Plan" of China pharmaceutical industry, we analyzed key points and our interpretation. Once achieved, it...
361 Views
Alphamab Co Ltd (9966.HK) - Some Points Worth the Attention
The article analyzed Alphamab Oncology in terms of its conservativeness on business operation and decision making in early stages, the concerns on...
238 Views
Shanghai Junshi Bioscience (1877.HK) - Will Junshi Progress or Go Backwards Instead?
The article mainly analyzed Junshi in terms of the pipeline, commercialization strategy, the talents, the outlook, the related concerns, as well as...
248 Views
Sino Biopharmaceutical (1177.HK) - The Business, The Concerns, The Insights on Biopharma Valuation
This article analyzed Sino Biopharmaceutical in terms of the business performance, short-term catalyst, concerns about the outlook, and insights on...
308 Views
Asia Ex-Japan Positioning: India & Tech at Record Highs
In this analysis, we provide a detailed overview of investor positioning among 96 active Asia Ex-Japan funds with combined AUM of $80bn.
167 Views